Sec. 2. Prohibition of illegal marketing and distribution practices with respect to opioids
1,420 words·~6 min read·
/bill/115/s/2691/is/section-2A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
Section 303 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 333 ) is amended by adding at the end the following: In this subsection, the term illegal marketing or distribution practice with respect to an opioid means— including in any advertisement, promotion, direct-to-consumer marketing materials, or other marketing material a representation that an opioid has no addiction-forming or addiction-sustaining liability or has less of an addiction-forming or addiction-sustaining liability than one or more other opioids, knowing the representation to be false, as determined by the Secretary, in consultation with the Commissioner, based on research, testimonials, and other evidence; supplying States or communities with a quantity of opioids that is not medically reasonable, as determined by the Secretary, in consultation with the Attorney General using, if applicable, data from the Automated Reports and Consolidated Ordering System of the Department of Justice; or failing to report to the Secretary any order or pattern of orders for the distribution of opioids that would cause a reasonable person to believe the opioids were not being dispensed in a medically reasonable manner.
It shall be unlawful for any person who manufactures or distributes an opioid to engage in an illegal marketing or distribution practice with respect to an opioid. Any person who violates paragraph (2)— if a natural person employed by an opioid manufacturer or distributor, shall be— subject to a civil penalty in an amount equal to the sum of— such person’s full amount of salary for each year during which such person engaged in illegal marketing or distribution practices with respect to an opioid product; and the amount by which the stock or other certificates of ownership interest of the person that is owned by the individual has increased in value during the period during which such person engaged in illegal marketing or distribution practices of an opioid product, without regard to whether the individual has sold any of the stock or certificates from such opioid manufacturer or distributor; and with respect to a violation that occurs on or after the date of enactment of the Opioid Crisis Accountability Act of 2018 , subject to the period of imprisonment specified under section 401 of the Controlled Substances Act that would be applicable for a violation of subsection
(a)of such section that involved the quantity of opioids that were involved in the illegal marketing or distribution practices with respect to an opioid; if not a natural person, shall be subject to a civil penalty in the amount equal to the sum of— $7,800,000,000; plus 25 percent of the total profit such person made on lawful sales of opioids in the United States during the period in which the person engaged in illegal marketing or distribution practices. If a person that is not a natural person violates paragraph (2), the court, without regard to the participation of such individuals in, or knowledge of such individuals of, the violation, shall— impose on the chief executive officer (or equivalent) of the person a civil penalty in an amount equal to the sum of— the salary of the individual during the period in which the person engaged in illegal marketing or distribution practices and such individual served as chief executive office; and the amount by which the stock or other certificates of ownership interest of the person that is owned by the individual has increased in value during the period that the person engaged in illegal marketing or distribution practices and such individual served as chief executive officer, without regard to whether the individual has sold any of the stock or certificates; impose on any executive other than the chief executive officer (or equivalent) who led the finance, research, marketing, or sales department of the person a civil penalty in the amount equal to the sum of— 25 percent of the salary of the individual during the period that the person engaged in illegal marketing or distribution practices and such individual served as such an executive; and 25 percent of the amount by which the stock or other certificates of ownership interest of the person that is owned by the individual has increased in value during the period that the person engaged in illegal marketing or distribution practices and such individual served as such an executive, without regard to whether the individual has sold any of the stock or certificates; and impose on any executive, including the chief executive officer (or equivalent) who led the finance, research, marketing, or sales department of the person during the calendar year in which a court enters a judgment that the person violated paragraph
(2)and who is not subject to a civil penalty under clause
(i)or (ii), a civil penalty in the amount equal to the sum of— 25 percent of the salary of the individual during the calendar year in which a court enters such judgment; and 25 percent of the amount by which the stock or other certificates of ownership interest of the person that is owned by the individual has increased in value during the calendar year in which a court enters such judgment. Any person described in clause
(i)or
(ii)of subparagraph
(A)shall be required to issue a public statement apologizing for their role in creating, sustaining, and exacerbating the opioid epidemic in the United States. . Immediately after the date of enactment of this Act, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs and in consultation with the Attorney General, acting through the Administrator of the Drug Enforcement Administration, shall begin investigating all opioid manufacturers and all executives employed by such manufacturers to determine whether any such manufacturers or executives, at any time before or after such date of enactment, violated subsection (h)(2) of section 303 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 333 ) (as added by subsection (a)). Subsection (h)(2) of section 303 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 333 ) (as added by subsection (a)) shall take effect on January 1, 1985, and shall have retroactive effect. There is established in the Treasury of the United States a fund, to be known as the Opioids Reimbursement Fund (referred to in this subsection as the Fund ), to be administered by the Secretary of Health and Human Services (referred to in this subsection as the Secretary ), in consultation with the Commissioner of Food and Drugs. In a manner consistent with section 3302(b) of title 31, United States Code, there shall be transferred to the Fund from the General Fund of the Treasury an amount equal to the amount of the civil penalties collected under subsection (h)(3) of section 303 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 333 ) (as added by subsection (a)), which shall remain available until expended. The Secretary, in consultation with the Commissioner of Food and Drugs, may, without further appropriation, use amounts in the Fund to combat the abuse of opioids in the United States, which may include transferring amounts from the Fund to other agencies to carry out programs, projects, and activities of the agencies to combat the abuse of opioids in the United States. In using amounts in the Fund, the Secretary shall give priority to providing funds for— programs, projects, and activities of the Substance Abuse and Mental Health Services Administration, the Department of Labor, and the Department of Justice; programs, projects, and activities that provide services to individuals directly affected by the abuse of opioids (including family members of such individuals); programs, projects, and activities of the Department of Education related to national activities for school safety, including such activities authorized under section 4631 of the Elementary and Secondary Education Act of 1965 ( 20 U.S.C. 7281 ) to help State and local educational agencies implement evidence-based opioid-abuse prevention strategies for schools in communities impacted by the opioid crisis, and particularly for any applicant who describes how such applicant would use the funds to prevent opioid abuse by students and address the mental health needs of students affected by opioid abuse with their families or communities; and Head Start programs, including Early Head Start programs, under the Head Start Act ( 42 U.S.C. 9831 et seq.), to provide additional qualified child care providers trained in trauma-informed care in States with the largest number of children and families affected by the opioid crisis in their communities. Amounts transferred to an agency under subparagraph
(A)shall remain available until expended.
Connectionstraces to 3
Traces to 3 documents
Citation graph
cites case law
Sec. 2
Prohibition of illegal marketing and distribution practices with respect to opioids
Cites 3Cited by 0 across 0 sources